Diabetes and Endocrine Treatment Specialists, Sandy, UT, USA.
Lab Med. 2023 May 2;54(3):327-332. doi: 10.1093/labmed/lmac115.
Monogenetic diabetes mellitus (DM) describes a collection of single-gene diseases marked by hyperglycemia presenting in childhood or adulthood and the absence of immunological markers of type 1 DM. Mutations in the human insulin gene INS give rise to two separate clinical syndromes: permanent neonatal DM, type 4 (PNDM4), and maturity-onset diabetes of youth, type 10 (MODY10); the former presents shortly after birth and the latter presents in childhood and adulthood. We describe a 40-year-old man in a kindred with high prevalence of DM who presented with severe hyperglycemia but not ketoacidosis or hypertriglyceridemia. Twelve years after initial presentation, the patient had elevated proinsulin and normal plasma C-peptide when nearly euglycemic on treatment with insulin glargine. A novel INS mutation, Gln65Arg, within the C-peptide region was identified. The INS (p.Gln65Arg) mutation may cause MODY10 by disrupting proinsulin maturation.
单基因糖尿病(DM)描述了一组单基因疾病,其特征是在儿童期或成年期出现高血糖,且无 1 型 DM 的免疫标志物。人胰岛素基因 INS 的突变导致两种独立的临床综合征:永久性新生儿 DM,4 型(PNDM4)和青年发病的成年型糖尿病,10 型(MODY10);前者在出生后不久出现,后者在儿童期和成年期出现。我们描述了一个有糖尿病高发家族史的 40 岁男性,他表现为严重高血糖,但无酮症酸中毒或高三酰甘油血症。初次就诊 12 年后,患者在接受甘精胰岛素治疗时接近正常血糖,但胰岛素原和正常血浆 C 肽升高。在 C 肽区域发现了一种新的 INS 突变,Gln65Arg。INS(p.Gln65Arg)突变可能通过破坏胰岛素原的成熟而导致 MODY10。